Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma

References

• World Cancer Research Fund International (eds.). Skin cancer statistics. 2022. Available under: https://www.wcrf.org/cancer-trends/skin-cancer-statistics/
   Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin2021713209249 10.3322/caac.21660 33538338
   PubMed Web of Science ®Google Scholar
• Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. S3-Leitlinien zur Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, AWMF Registernumer: 032/024OL. 2020.
   Google Scholar
• Smalley KSM, Eroglu Z, Sondak VKCombination therapies for melanoma: a new standard of care?Am J Clin Dermatol201617299105 10.1007/s40257-016-0174-8 26860106 4805442
   PubMed Web of Science ®Google Scholar
• Rubio-Rodríguez D, De Diego Blanco, Pérez M, Rubio-Terrés CCost-effectiveness of drug treatments for advanced melanoma: a systematic literature reviewPharmacoeconomics2017359879893 10.1007/s40273-017-0517-1 28551858
   PubMed Web of Science ®Google Scholar
• Adcock L, Seal K. Canadian agency for drugs and technologies in health; 2017. Available under: https://www.ncbi.nlm.nih.gov/books/NBK525603/
   Google Scholar
• Gorry C, McCullagh L, Barry MEconomic evaluation of systemic treatments for advanced melanoma: a systematic reviewValue Health.20202315260 10.1016/j.jval.2019.07.003 31952674
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.Improved survival with ipilimumab in patients with metastatic melanomaN Engl J Med20103638711723 1:CAS:528:DC%2BC3cXhtVCrtrbN 10.1056/NEJMoa1003466 20525992 3549297
   PubMed Web of Science ®Google Scholar
• Schadendorf DEine Übersicht über Therapiefortschritte in den letzten 50 Jahren beim Metastasierten MelanomDrug Res20166613132
   Google Scholar
• Hauschild AImmunonkologie beim malignen Melanom: Von der Monotherapie zur Kombinationstherapie - aktuelle Studiendaten und FragestellungenOncol Res Treat.201639Suppl. 427 10.1159/000449457 27780161
   PubMedGoogle Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med201537312334 10.1056/NEJMoa1504030 26027431 5698905
   PubMed Web of Science ®Google Scholar
• European Commission. Durchführungsbeschluss der Kommission vom 11.5.2016 über die Änderung der mit dem Beschluss C(2015)4299(final) erteilten Zulassung des Humanarzneimittels „Opdivo - Nivolumab“. 2016. Available under: https://ec.europa.eu/health/documents/community-register/html/h1014.htm
   Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al.Improved overall survival in melanoma with combined dabrafenib and trametinibN Engl J Med201537213039 10.1056/NEJMoa1412690 25399551
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al.Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLancet20153869992444451 1:CAS:528:DC%2BC2MXpsVyrt7k%3D 10.1016/S0140-6736(15)60898-4 26037941
   PubMed Web of Science ®Google Scholar
• Klein O, Clements A, Menzies AM, O’Toole S, Kefford RF, Long GVBRAF inhibitor activity in V600R metastatic melanomaEur J Cancer.201349510731079 1:CAS:528:DC%2BC38XhvVaju73L 10.1016/j.ejca.2012.11.004 23237741
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DGThe PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLOS Med200967 10.1371/journal.pmed.1000097 19621072 2707599
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al.Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialLancet Oncol201617912481260 1:CAS:528:DC%2BC28Xht1ygsL%2FL 10.1016/S1470-2045(16)30122-X 27480103
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Dréno B, Larkin J, Ribas A, Liszkay G, Maio M, et al.5-Year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM studyClin Cancer Res2021271952255235 1:CAS:528:DC%2BB3MXisFanur3F 10.1158/1078-0432.CCR-21-0809 34158360 9401485
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al.Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialLancet Oncol2018195603615 1:CAS:528:DC%2BC1cXlslKltr4%3D 10.1016/S1470-2045(18)30142-6 29573941
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al.Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyAnn Oncol201728716311639 1:STN:280:DC%2BC1crksVartw%3D%3D 10.1093/annonc/mdx176 28475671 5834102
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al.Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialLancet Oncol2018191114801492 1:CAS:528:DC%2BC1cXhvFOqsr3K 10.1016/S1470-2045(18)30700-9 30361170
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al.Five-year survival with combined nivolumab and ipilimumab in advanced melanomaN Engl J Med20193811615351546 1:CAS:528:DC%2BC1MXitVShs7jF 10.1056/NEJMoa1910836 31562797
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al.Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanomaJ Clin Oncol2022402127137 1:CAS:528:DC%2BB38XhslKltr8%3D 10.1200/JCO.21.02229 34818112
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyLancet Oncol201920810831097 1:CAS:528:DC%2BC1MXhtF2kurbM 10.1016/S1470-2045(19)30274-8 31221619
   PubMed Web of Science ®Google Scholar
• Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, et al.Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 studyAnn Oncol2021323384394 1:CAS:528:DC%2BB38XhvVKrurg%3D 10.1016/j.annonc.2020.12.004 33309774
   PubMed Web of Science ®Google Scholar
• Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, et al.an economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage iii melanoma in the USAClin Drug Investig.2020407629643 1:CAS:528:DC%2BB3cXpvVansbw%3D 10.1007/s40261-020-00922-6 32418051 7311503
   PubMed Web of Science ®Google Scholar
• Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, et al.A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss settingBr J Dermatol2015173614621470 1:STN:280:DC%2BC287os1egsg%3D%3D 10.1111/bjd.14152 26332527
   PubMed Web of Science ®Google Scholar
• Paly VF, Hikichi Y, Baker T, Itakura E, Chandran N, Harrison JEconomic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in JapanJ Med Econ2020231215421552 10.1080/13696998.2020.1830781 33000994
   PubMed Web of Science ®Google Scholar
• Quon PL, Xiao Y, Sorensen S, Monfared AATEconomic evaluation of nivolumab plus ipilimumab combination as first-line treatment for patients with advanced melanoma in CanadaPharmacoEconomics—Open.201933321331 10.1007/s41669-018-0112-1 30617952 6710483
   PubMed Web of Science ®Google Scholar
• Wu B, Shi LFrontline BRAF testing-guided treatment for advanced melanoma in the era of immunotherapies: a cost-utility analysis based on long-term survival dataJAMA Dermatol20201561111771184 10.1001/jamadermatol.2020.2398 32697281 7376469
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P, et al.Societal preference values for advanced melanoma health states in the United Kingdom and AustraliaBr J Cancer20091013387389 1:STN:280:DC%2BD1MrhslWmsQ%3D%3D 10.1038/sj.bjc.6605187 19603025 2720221
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, et al.Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyAnn Oncol2014253700706 1:STN:280:DC%2BC2cvivVajtA%3D%3D 10.1093/annonc/mdt580 24504441 4433512
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al.Estimating an EQ-5D population value set: the case of JapanHealth Econ2002114341353 10.1002/hec.673 12007165
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al.Relatlimab and nivolumab versus nivolumab in untreated advanced melanomaN Engl J Med202238612434 1:CAS:528:DC%2BB38XhtFaltr4%3D 10.1056/NEJMoa2109970 34986285 9844513
   PubMed Web of Science ®Google Scholar
• Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, et al.Can we accurately predict cost effectiveness without access to overall survival data? The case study of nivolumab in combination with ipilimumab for the treatment of patients with advanced melanoma in EnglandPharmacoEconomics—Open.2019314354 1:STN:280:DC%2BC1MfmtV2qtQ%3D%3D 10.1007/s41669-018-0080-5 29790020
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al.Five-year outcomes with dabrafenib plus trametinib in metastatic melanomaN Engl J Med20193817626636 1:CAS:528:DC%2BC1MXhs1GqsbbO 10.1056/NEJMoa1904059 31166680
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al.Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyLancet Oncol201920912391251 1:CAS:528:DC%2BC1MXhsVeltb7K 10.1016/S1470-2045(19)30388-2 31345627
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al.Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet20203951024018351844 1:CAS:528:DC%2BB3cXhtFGgtbvI 10.1016/S0140-6736(20)30934-X
   PubMed Web of Science ®Google Scholar
• Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, et al.Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600–mutant unresectable or metastatic melanomaJ Clin Oncol2022401314281438 1:CAS:528:DC%2BB38Xhslyru7rF 10.1200/JCO.21.01601 35030011 9061149
   PubMed Web of Science ®Google Scholar